ATE120954T1 - Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids. - Google Patents

Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.

Info

Publication number
ATE120954T1
ATE120954T1 AT92306646T AT92306646T ATE120954T1 AT E120954 T1 ATE120954 T1 AT E120954T1 AT 92306646 T AT92306646 T AT 92306646T AT 92306646 T AT92306646 T AT 92306646T AT E120954 T1 ATE120954 T1 AT E120954T1
Authority
AT
Austria
Prior art keywords
aids
treatment
produce
fatty acids
medicinal product
Prior art date
Application number
AT92306646T
Other languages
English (en)
Inventor
David Frederick Horrobin
Michael David C O Efam Winther
Park Po Box Industrial
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10698951&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE120954(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of ATE120954T1 publication Critical patent/ATE120954T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Junction Field-Effect Transistors (AREA)
  • Amplifiers (AREA)
AT92306646T 1991-07-24 1992-07-20 Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids. ATE120954T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919116054A GB9116054D0 (en) 1991-07-24 1991-07-24 Preparation of fatty acid medicaments

Publications (1)

Publication Number Publication Date
ATE120954T1 true ATE120954T1 (de) 1995-04-15

Family

ID=10698951

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92306646T ATE120954T1 (de) 1991-07-24 1992-07-20 Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.

Country Status (12)

Country Link
EP (1) EP0524796B1 (de)
JP (1) JPH05194244A (de)
KR (1) KR930001902A (de)
AT (1) ATE120954T1 (de)
AU (1) AU1968992A (de)
CA (1) CA2073913A1 (de)
DE (1) DE69202019D1 (de)
FI (1) FI923357L (de)
GB (1) GB9116054D0 (de)
IE (1) IE922250A1 (de)
NO (1) NO922936L (de)
ZA (1) ZA925562B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214062A (en) * 1992-04-08 1993-05-25 Clintec Nutrition Co. Method and composition for treating immune disorders, inflammation and chronic infections
US5674901A (en) * 1995-06-01 1997-10-07 Wisconsin Alumni Research Foundation Methods of treating animals to maintain or increase CD-4 and CD-8 cell populations
GB9211229D0 (en) * 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
GB9304746D0 (en) * 1993-03-09 1993-04-28 Scotia Holdings Plc Treatment of viral infections
GB9318611D0 (en) * 1993-09-08 1993-10-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5856149A (en) * 1995-06-01 1999-01-05 Wisconsin Alumni Research Foundation Method of producing conjugated fatty acids
DE19611953A1 (de) * 1996-03-26 1997-10-02 Beiersdorf Ag Verwendung von ungesättigten Monocarbonsäuren gegen Superinfektionen
US7381413B1 (en) 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
ES2209658B1 (es) * 2002-12-05 2005-10-01 Proyecto Empresarial Brudy, S.L. Utilizacion del acido docosahexaenoico como principio activo para el tratamiento de la lipodistrofia.
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
EP1597978A1 (de) 2004-05-17 2005-11-23 Nutricia N.V. Synergie von GOS und polyfruktose
US8252769B2 (en) 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
CA2570208A1 (en) * 2004-06-22 2005-12-29 N.V. Nutricia Improvement of barrier integrity in hiv patients
JP2006282644A (ja) * 2005-04-05 2006-10-19 Idemitsu Kosan Co Ltd 疲労回復剤
WO2007119378A1 (ja) 2006-03-15 2007-10-25 Suntory Limited リボフラビンとセサミン類とを含有する組成物
AU2008211199A1 (en) 2007-01-26 2008-08-07 The Regents Of The University Of Colorado Methods of modulating immune function
AU2008239318B2 (en) 2007-03-15 2013-10-03 Suntory Holdings Limited Anti-fatigue agent
US9296776B2 (en) 2007-07-09 2016-03-29 Eastern Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties
WO2009038090A1 (ja) 2007-09-19 2009-03-26 Suntory Holdings Limited セサミン類とアラキドン酸類を含有する組成物
JP2009073747A (ja) * 2007-09-19 2009-04-09 Suntory Ltd アラキドン酸を有効成分とする抗疲労剤
WO2020077420A1 (en) * 2018-10-16 2020-04-23 MOREIRA, Nivaldo José Extract of jatropha curcas seed oil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4017979A1 (de) * 1990-06-05 1991-12-12 Meyer Lucas Gmbh & Co Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen

Also Published As

Publication number Publication date
KR930001902A (ko) 1993-02-22
JPH05194244A (ja) 1993-08-03
AU1968992A (en) 1993-01-28
CA2073913A1 (en) 1993-01-25
EP0524796A1 (de) 1993-01-27
IE922250A1 (en) 1993-01-27
ZA925562B (en) 1993-04-28
GB9116054D0 (en) 1991-09-11
NO922936D0 (no) 1992-07-23
FI923357A7 (fi) 1993-01-25
DE69202019D1 (de) 1995-05-18
FI923357A0 (fi) 1992-07-23
FI923357L (fi) 1993-01-25
NO922936L (no) 1993-01-25
EP0524796B1 (de) 1995-04-12

Similar Documents

Publication Publication Date Title
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ES2114616T3 (es) Acidos dicarboxilicos alifaticos insaturados.
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
DE69632236D1 (de) Verwendung von dha in der behandlung von dyslexie
EP1852121A3 (de) Flüssige Analoge zur Behandlung viraler Infektionen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE184193T1 (de) Verwendung von n-acylaminoalkoholen zur herstellung eines arzneimittels zur behandlung von mastzellerkrankungen
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ATE135223T1 (de) Arzneimittel zur behandlung von hyperlipidämie und/oder atherosklerose
ATE69550T1 (de) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen.
DE69004425D1 (de) Verwendung von c-20 bis c-26-aliphatischen alkoholen zur herstellung eines arzneimittels zur behandlung viraler infektionen.
DE3856052D1 (de) Anwendung des N-n-butyl-Derivates von Desoxynojirimycin zur Herstellung eines Arzneimittels zur Inhibierung von HIV-Virus
ATE192929T1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
ATE160090T1 (de) Verwendung von l-carnitine und acyl-l-carnitinen zur behandlung von patienten die an aids- verwandten syndromen leiden und von asymptomatischen hiv-seropositiven patienten
ATE183390T1 (de) Verwendung einer kombination von antineoplastonen zur herstellung eines arzneimittels zur behandlung der neurofibromatose
ATE133334T1 (de) Gammalinolensäure zur herstellung eines medikaments zur verhinderung von wiederverschluss von arterien
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
IL102815A0 (en) Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
ATE137968T1 (de) Verwendung von l-2-oxothiazolidine-4-carboxylate zur herstellung eines arzneimittels zur behandlung von latenten hiv-infektionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties